 Zacks Investment Research downgraded shares of Allakos NASDAQ:ALLK from a hold rating to a sell rating in a research report sent to investors on Monday morning, Zacks.com reports. According to Zacks, Allakos Inc. is a clinical stage bio-technology company. It discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases. Allakos ... 